Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders - Patent Pending

United States Patent Application 20040235956
Kind Code A1
Quay, Steven C. November 25, 2004
Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
Abstract
Methods and compositions are provided for prophylaxis and treatment of breast cancer involving administration of a therapeutically effective amount of carbetocin and/or other long-acting oxytocin analogues. 1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin (carbetocin) and/or other long-acting oxytocin analogues are formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to inhibit initiation or growth of breast cancer in the patient. The carbetocin and/or other long-acting oxytocin analogues may also be formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, prevent or alleviate the symptoms of a psychiatric disorder in the patient. Carbetocin may be administered prophylactically or to treat existing conditions in patients by a variety of administration modes, including intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery methods and formulations. Preferably, the carbetocin is administered to a mucosal surface of the patient via intranasal delivery. For this purpose, pharmaceutical compositions are provided for intranasal delivery that incorporate carbetocin in a powder or aqueous formulation for intranasal delivery.
Inventors: Quay, Steven C.; (Edmonds, WA)
Correspondence Name and Address: Jeffrey J. King
GRAYBEAL JACKSON HALEY LLP
Suite 350
155-108th Avenue NE
Bellevue
WA
98004-5901
US
Assignee Name and Adress: Atossa Healthcare, Inc.
Serial No.: 879814
Series Code: 10
Filed: June 28, 2004
U.S. Current Class: 514/573
U.S. Class at Publication: 514/573
Intern'l Class: A61K 031/557